Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

This amounts to one of the most significant federal government investments in the behavioral health sector in history. For ...

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

Asian American populations, particularly when broken down into ethnic groups, have allergy health outcomes that are distinct ...

The Biden administration’s final regulation affecting the Medicare Advantage industry would come with a much lighter touch ...